文献速递颈动脉与弓上血管

颈动脉内膜切除术后再狭窄的经股动脉支架与经颈动脉血运重建疗效比较

Outcomes of transfemoral carotid artery stenting and transcarotid artery revascularization for restenosis after prior ipsilateral carotid endarterectomy.
PubMed 文献 · J Vasc Surg · 2021-09-08

本研究基于血管质量倡议数据库,比较了既往同侧颈动脉内膜切除术后再狭窄患者接受经股动脉颈动脉支架(TfCAS)与经颈动脉血运重建(TCAR)的围手术期结局。共纳入3508例患者,TCAR组30天卒中/死亡复合结局、卒中/死亡/TIA及卒中/死亡/心梗复合结局均低于TfCAS组,校正后TCAR组TIA风险显著降低,其余结局相似。

要点

  • TCAR组30天卒中/死亡复合结局为1.6%,低于TfCAS组的2.7%。
  • 校正混杂因素后,TCAR组30天TIA风险显著低于TfCAS组(aOR 0.17)。
  • 两组在卒中、死亡及卒中/死亡/心梗复合结局方面安全性相似。

核心结论

  • 对于既往同侧CEA后再狭窄患者,TCAR与TfCAS相比可降低30天TIA风险。
  • 两种术式在卒中、死亡及卒中/死亡/心梗等其余围手术期结局上安全性相似。

研究设计与样本

  • 回顾性队列研究,基于Vascular Quality Initiative数据库,纳入2016年1月至2020年8月期间因同侧CEA后再狭窄接受TfCAS或TCAR的患者。
  • 共纳入3508例患者,其中TfCAS组1834例,TCAR组1674例。
  • 主要结局为30天卒中/死亡复合结局,采用多因素logistic回归校正混杂因素。

主要发现

  • TCAR组较TfCAS组年龄更大(平均71.6岁 vs 70.2岁,P < .001),症状性比例更低(27% vs 46%,P < .001)。
  • TCAR组30天卒中/死亡复合结局(1.6% vs 2.7%,P = .025)、卒中/死亡/TIA(1.8% vs 3.3%,P = .004)、卒中/死亡/心梗(2.1% vs 3.2%,P = .048)均低于TfCAS组。
  • TCAR组卒中发生率(1.3% vs 2.3%,P = .031)和TIA发生率(0.2% vs 0.7%,P = .031)均低于TfCAS组。
  • 无症状患者中,TCAR组卒中发生率(0.6% vs 1.4%,P = .042)和卒中/TIA复合结局(0.8% vs 1.8%,P = .036)显著低于TfCAS组。
  • 症状性患者中,TCAR组TIA发生率(0% vs 1%,P = .038)显著低于TfCAS组。

临床怎么用

  • 对于既往同侧CEA后再狭窄的高危患者,TCAR可作为TfCAS的安全替代方案。
  • 选择术式时需权衡TIA风险降低与患者个体特征,TCAR在降低TIA方面可能更具优势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Restenosis after carotid endarterectomy (CEA) poses unique therapeutic challenges, with no specific guidelines available on the operative approach. Traditionally, transfemoral carotid artery stenting (TfCAS) has been regarded as the preferred approach to treating restenosis after CEA. Recently, transcarotid artery revascularization with a flow-reversal neuroprotection system (TCAR) has gained popularity as an effective alternative treatment modality for de novo carotid artery stenosis. The aim of the present study was to compare the contemporary perioperative outcomes of TfCAS and TCAR in patients with prior ipsilateral CEA. METHODS: The Vascular Quality Initiative database was reviewed for patients who had undergone TfCAS and TCAR for restenosis after prior ipsilateral CEA between January 2016 and August 2020. The primary outcome was the 30-day composite outcome of stroke and death. The secondary outcomes included 30-day stroke, transient ischemic attack (TIA), myocardial infarction (MI), death, and composite 30-day outcomes of stroke, death, and TIA, stroke and TIA, and stroke, death, and MI. Multivariable logistic regression models were used to evaluate the outcomes of interest after adjustment for potential confounders and baseline differences between cohorts. RESULTS: Of 3508 patients, 1834 and 1674 had undergone TfCAS and TCAR, respectively. The TCAR cohort was older (mean age, 71.6 years vs 70.2 years; P < .001) and less likely to be symptomatic (27% vs 46%; P < .001), with a greater proportion taking aspirin (92% vs 88%; P = .001), a P2Y12 inhibitor (89% vs 80%; P < .001), and a statin (91% vs 87%; P = .002) compared with the TfCAS cohort. Perioperatively, the TCAR cohort had had lower 30-day composite outcomes of stroke/death (1.6% vs 2.7%; P = .025), stroke/death/TIA (1.8% vs 3.3%; P = .004), and stroke/death/MI (2.1% vs 3.2%; P = .048), primarily driven by lower rates of stroke (1.3% vs 2.3%; P = .031) and TIA (0.2% vs 0.7%; P = .031). Among asymptomatic patients, the incidence of stroke (0.6% vs 1.4%; P = .042) and the composite of stroke/TIA (0.8% vs 1.8%; P = .036) was significantly lower after TCAR than TfCAS, and TCAR was associated with a lower incidence of TIA (0% vs 1%; P = .038) among symptomatic patients. On adjusted analysis, the TCAR cohort had lower odds of TIA (adjusted odds ratio, 0.17; 95% confidence interval, 0.04-0.74; P = .019). CONCLUSIONS: Among patients undergoing carotid revascularization for restenosis after prior ipsilateral CEA, TCAR was associated with decreased odds of 30-day TIA compared with TfCAS. However, the two treatment approaches were similarly safe in terms of the remaining perioperative outcomes, including stroke and death and stroke, death, and MI. Our results support the safety and efficacy of TCAR in this subset of patients deemed at high risk of reintervention.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Chang H, Rockman CB, Veith FJ, et al. Outcomes of transfemoral carotid artery stenting and transcarotid artery revascularization for restenosis after prior ipsilateral carotid endarterectomy. J Vasc Surg. 2021. PMID: 34506900. doi:10.1016/j.jvs.2021.07.245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。